Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0MQGYS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-LAMP-1 antibody |
|||||
| Antigen Name | LAMP-1 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SAR428926 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires advanced solid tumors without standard options, with HER2- cancers (escalation) or SAR428926-target-antigen+ tumors (expansion, including TNBC/prostate/CRC/ovarian/NSCLC). Measurable lesions (RECIST v1.1) and biopsy-accessible lesions (expansion, NSCLC exempt) are mandatory. Exclusions cover prior DM1/DM4-ADC therapy, active HBV/HCV/HIV, corneal/neuropathy/cardiac issues (LVEF<50%), CYP3A inhibitor use, contact lens dependence, inadequate organ function, and contraindications to ocular medications (e.g., glaucoma). Reproductive-age participants must comply with pregnancy prevention protocols.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02575781 | Clinical Status | PHASE1 | ||
| Clinical Description |
A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The safety evaluation focuses on dose-limiting adverse events (4-week window, escalation cohort) and corneal AE impact (8-week window). Efficacy in the expansion cohort involves RECIST v1.1-assessed ORR with bimonthly tumor imaging until progression or 36 months maximum duration.
|
||||
| Other Endpoint |
Long-term AE monitoring spans 3 years, alongside PK assessments (Cmax, tmax, Ctrough, AUC0-14, CL, and accumulation ratios) at 2-month intervals. Corneal event documentation (12 weeks) includes preventive measure analysis, while preliminary tumor response (escalation, 2 months) supplements RECIST v1.1 tracking.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT02575781 | Clinical Status | Phase 1 | ||
| Clinical Description |
A first-in-human phase 1 dose escalation study of SAR428926 in patients with advanced solid tumors.
|
||||
References